Details

Autor(en) / Beteiligte

• Semenova, Ekaterina A.
• Kwon, Min-chul
• Monkhorst, Kim
• Song, Ji-Ying
• Bhaskaran, Rajith
• Krijgsman, Oscar
• Kuilman, Thomas
• Peters, Dennis
• Buikhuisen, Wieneke A.
• Smit, Egbert F.
• Pritchard, Colin
• Cozijnsen, Miranda
• van der Vliet, Jan
• Zevenhoven, John
• Lambooij, Jan-Paul
• Proost, Natalie
• van Montfort, Erwin
• Velds, Arno
• Huijbers, Ivo J.
• Berns, Anton

Titel

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

Ist Teil von

• Cell reports (Cambridge), 2016-07, Vol.16 (3), p.631-643

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and Trp53 show frequent amplifications of the Nfib and Mycl genes. Here, we report that, although overexpression of either transcription factor accelerates tumor growth, NFIB specifically promotes metastatic spread. High NFIB levels are associated with expansive growth of a poorly differentiated and almost exclusively E-cadherin (CDH1)-negative invasive tumor cell population. Consistent with the mouse data, we find that NFIB is overexpressed in almost all tested human metastatic high-grade neuroendocrine lung tumors, warranting further assessment of NFIB as a tumor progression marker in a clinical setting. [Display omitted] •NFIB drives tumor initiation and progression in mouse models of SCLC•NFIB enhances metastasis and changes the metastatic profile•NFIB promotes dedifferentiation and invasion in SCLC•NFIB marks stage III/IV high-grade neuroendocrine carcinomas in patients SCLC is a highly malignant cancer with an unmet need for better intervention strategies. Semenova et al. report that the transcription factor NFIB drives SCLC growth and metastasis, defines an aggressive tumor compartment in mice, and marks a subgroup of high-grade pulmonary neuroendocrine tumors (pNETs) in patients.